Company type | Subsidiary |
---|---|
Headquarters |
,
United States
|
Key people | Brian Alexander (CEO) |
Products | FoundationOne CDx FoundationOne Liquid FoundationOne Heme Foundation Insights FoundationSmartTrials |
Revenue | $152.9 million (2017)[1] |
Owners | Roche |
Website | foundationmedicine |
Foundation Medicine, Inc. is an American company based in Cambridge, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.[2]
Foundation Medicine was founded in Cambridge, Massachusetts.[3] The company was conceived after Broad Institute researchers Levi Garraway and Matthew Meyerson published a 2007 paper detailing a method for large-panel testing of 238 DNA mutations.[4]
Foundation Medicine launched in 2010 with a $25 million Series A financing led by Third Rock Ventures.[5] The company released its first commercial assay, or test, called FoundationOne in 2012.[6] The company also began partnering with pharmaceutical companies to analyze patient samples.[4] The first such program was piloted with Novartis in 2011,[5] and by 2018, the company had more than 30 partnerships.[7]
Foundation Medicine launched its second test, a hematological biomarker assay called FoundationOneHeme, in 2013.[8] The company held its initial public offering in August 2013.[9] The following year, Priority Health in Michigan became the first healthcare plan in the United States to cover the company's tests.[10]
In 2016, using FoundationCore data, Foundation Medicine released anonymized records detailing genomic data on cancers from 18,000 adult patients to the National Cancer Institute's (NCI) Genomic Data Commons (GDC) portal.[11]
In 2018, Roche acquired Foundation Medicine, and currently operates it as a subsidiary.[12][13]
Guardant Health sued Foundation Medicine over patents in 2019–2020.[14][15] In 2021, Guardant Health licensed intellectual property to Foundation Medicine for $25 million in a settlement.[16]
Foundation Medicine's products include genomic tests for solid tumors and blood-based cancers and sarcomas,[17] as well as data services.
Foundation, founded in Cambridge, Mass., in 2010